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Enumeration of the colony-forming units–fibroblast
from mouse and human bone marrow in normal and
pathological conditions
Sergei A. Kuznetsov a,⁎, Mahesh H. Mankani a,1,
Paolo Bianco b, Pamela G. Robey aa Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of
Health, Department of Health and Human Services, 30 Convent Dr MSC 4370 Bethesda, MD 20892-4370, USA
b Dipartimento di Medicina Sperimentale e Patologia, Università La Sapienza, 00161 Roma, ItalyReceived 17 December 2007; received in revised form 3 July 2008; accepted 31 July 2008Abstract Bone marrow stromal cell populations, containing a subset of multipotential skeletal stem cells, are
increasingly contemplated for use in tissue engineering and stem cell therapy, whereas their involvement in the
pathogenetic mechanisms of skeletal disorders is far less recognized. We compared the concentrations of stromal
clonogenic cells, colony forming units–fibroblast (CFU-Fs), in norm and pathology. Initially, culture conditions
were optimized by demonstrating that fetal bovine serum heat inactivation could significantly repress colony formation.
Using non-heat-inactivated fetal bovine serum, the concentration of CFU-Fs (colony-forming efficiency, CFE) ranged from
3.5 ± 1.0 to 11.5 ± 4.0 per 1 × 105 nucleated cells in five inbred mouse strains. In four transgenic lines with profound bone
involvement, CFE was either significantly reduced or increased compared to wild-type littermates. In normal human
donors, CFE decreased slightly with age and averaged 52.2 ± 4.1 for children and 32.3 ± 3.0 for adults. CFE was significantly
altered in patients with several skeletal, metabolic, and hematological disorders: reduced in congenital generalized
lipodystrophy, achondroplasia (SADDAN), pseudoachondroplasia, and Paget disease of bone and elevated in alcaptonuria
and sickle cell anemia. Our findings indicate that under appropriate culture conditions, CFE values may provide useful
insights into bone/bone marrow pathophysiology.
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Bone marrow stromal cells [BMSCs, renamed in the1990s as
“mesenchymal stem cells” (Caplan, 1991)] contain a sub-
population of multipotential skeletal stem cells (SSCs) that
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doi:10.1016/j.scr.2008.07.007bone, cartilage, fat, and hematopoiesis-supportive reticular
stroma (Bianco and Robey, 2004; Friedenstein, 1980). Due to
the BMSC capacity for ample ex vivo expansion, and the
presence of SSCs within their populations, BMSCs have
become a centerpiece of innovative therapeutic approaches
such as tissue engineering and gene therapy (Bianco et al.,
2001; Krebsbach et al., 1999). Far less recognized is BMSC/
SSC involvement in skeletal and marrow-related pathologies.
Yet when BMSCs/SSCs carrying natural or targeted genetic
changes are transplanted in vivo into the subcutis of
immunodeficient mice, they generate ectopic ossicles that.
Table 1 Normal donors
Donor Age
(years)
Gender Site CFE/1×105 nucleated
cells (mean±SEM)
Pediatric (age below 18 years)
1 0.5 M Iliac crest 68.0±4.0
2 1 M Finger 101.3±2.7
3 1 M Finger 93.3±4.4
4 6 F Iliac crest 61.5±3.5
5 7 F Iliac crest 66.8±1.8
6 7 M Iliac crest 66.8±3.4
7 7 M Iliac crest 25.3±1.5
8 8 M Iliac crest 32.8±2.2
9 9 F Iliac crest 21.0±2.3
10 11 F Iliac crest 38.3±2.3
11 12 F Iliac crest 11.3±1.7
12 13 F Iliac crest 67.5±3.2
13 13 F Iliac crest 18.3±2.5
14 14 M Iliac crest 34.5±2.0
15 14 F Iliac crest 95.5±1.2
16 15 F Iliac crest 21.8±1.2
Average 52.2±4.1
Adult (age above 18 years)
1 29 F Iliac crest 44.0±2.5
2 38 F Iliac crest 26.3±3.5
3 42 M Sternum 56.8±6.1
4 45 F Iliac crest 12.3±1.8
5 48 F Iliac crest 21.1±0.4
6 48 M Femur 25.7±4.5
7 52 F Iliac crest 30.7±3.3
8 76 F Iliac crest 37.5±1.6
Average 32.3±3.0
CFE, colony-forming efficiency.
84 S.A. Kuznetsov et al.recapitulate pathological features of the original lesion;
thus, abnormal BMSCs/SSCs can single-handedly re-create a
disease (Bianco et al., 2000; Holmbeck et al., 1999;
Kuznetsov et al., 2004; Riminucci et al., 2001). Moreover, in
several bone disorders, such as fibrous dysplasia of bone,
hyperparathyroidism, and early stages of Paget disease,
distinct changes in the number, organization, and apparent
function of marrow stromal cells are as prominent as the
changes in bony structures themselves (Bianco and Robey,
1999; Robey and Bianco, 1999). Consequently, analysis of
marrow stroma, both qualitative and quantitative, provides
another way to probe pathogenetic mechanisms related to
SSC activity in both humans and transgenic animals.
In low-density bone marrow cell cultures, discrete
colonies of adherent fibroblast-like BMSCs are formed,
each colony arising from a single precursor cell termed a
colony-forming unit–fibroblast (CFU-F) (Friedenstein, 1973,
1976; Friedenstein et al., 1978; Latsinik et al., 1986). The
number of colonies formed per a definitive number of
marrow cells plated, the colony-forming efficiency (CFE),
thereby defines the CFU-F content among marrow cells,
representing in vitro enumeration of a clonogenic subset of
in vivo marrow stromal cell populations. Furthermore, it
has been demonstrated that CFU-F populations are not
homogeneous but rather contain a hierarchy of progenitors
including multipotential SSCs and committed progenitors. By
in vivo analyses of clonal strains established by single CFU-Fs,
SSCs constitute from one-tenth to one-third of all CFU-Fs
(Bennett et al., 1991; Chailakhian et al., 1978; Gerasimov Iu
et al., 1986; Kuznetsov et al., 1997b, 2004). To date, there
are no markers that can be used prospectively to separate
multipotential CFU-Fs, or SSCs, from more committed CFU-
Fs. Thus, the CFE assay is currently the closest approximation
to the determination of the concentration of SSCs in bone
marrow (Bianco and Robey, 2004).
CFE values are based on in vitro proliferation of CFU-Fs
and their descendents and are, therefore, substantially
dependent on the culture conditions. To optimize the
parameters of the CFE assay, we first analyzed the effects
of a major component of cell culture media, fetal bovine
serum (FBS), on BMSC colony formation. We found for the
first time that in many different lots, heat inactivation had a
deleterious effect on CFE in mouse and human cultures. We
then extended our determination of CFE using several inbred
mouse strains and transgenic lines with substantial bone
involvement, as well as normal human donors and patients
with several skeletal, metabolic, and hematological dis-
orders, in which CFE has not been previously described. This
study was, by design, limited to the analysis of BMSC colony
formation and CFU-F concentration under a variety of
conditions. Our results indicate that, under appropriate
culture conditions, CFE values are considerably and variably
affected in various disease states in mice and humans.
Results
Comparison of the effects of different lots of FBS on
murine and human CFE
We studied the effects of 11 FBS lots (non-heat-inactivated)
on BMSC colony formation using a mouse bone marrow cellsuspension prepared from two FVB/N mice (6-week-old
females) and a human bone marrow cell suspension from a
single normal donor (normal adult donor 8, 76-year-old
female, Table 1). Depending on the FBS lot, mouse CFE varied
from 4.3 to 7.5 per 1 × 105 nucleated marrow cells (Fig. 1A).
The two “worst” lots (Nos. 1 and 2) supported significantly
lower CFE than the three “best” lots (Nos. 5, 7, and 9), while
lots 3 through 11 generated CFE values not significantly
different from each other. Human CFE varied from 12.9 to
40.6 per 1 × 105 nucleated marrow cells (Fig. 1B). Similar to
mouse cultures, the two “worst” lots (3 and 5) supported
significantly lower CFE than all remaining lots, which
generated CFE comparable to one another. Interestingly,
lot 5 was among the most effective in mouse cultures but was
among the least effective in human cultures. Vice versa, lot 2
supported the highest human CFE but the lowest mouse CFE.
Effect of FBS heat inactivation
In mouse cultures, heat inactivation reduced CFE in all FBS
lots studied; for four lots, the reduction was statistically
significant (Fig. 1A). In human cultures, heat inactivation
significantly decreased CFE in six FBS lots, including two lots
(3 and 4) that totally lost their ability to support BMSC colony
formation (Fig. 1B). In no instance did heat inactivation
Figure 1 Mouse and human CFE in medium with various FBS
lots. Mouse and human bone marrow cells were plated in
medium with FBS of 1 of 11 lots, either noninactivated or heat
inactivated. (A) Mouse cultures. Mouse bone marrow cells from
two FVB/N mice were plated in triplicate. Statistically sig-
nificant differences between noninactivated lots: No. 1 from 5,
Pb0.05; 1 from 9, Pb0.01; 2 from 5, Pb0.01; 2 from 7, Pb0.05;
2 from 9, Pb0.001. (B) Human cultures. Human bone marrow
cells from a single donor were plated in quadruplicate.
Statistically significant differences between noninactivated
lots: No. 3 from all other lots (except 5), Pb0.001; 5 from all
other lots (except 3), Pb0.001. ⁎Pb0.05; ⁎⁎Pb0.01; ⁎⁎⁎Pb0.001.
Figure 2 Human CFE in cultures from several donors with
noninactivated and heat-inactivated FBS. Bone marrow cells
from five donors were plated in triplicate in medium containing
FBS lot 1, either noninactivated or heat inactivated. The
differences between the noninactivated and the heat-
inactivated groups were statistically significant only for the
first donor. ⁎Pb0.05.
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heat inactivation-induced loss of activity did not correlate
with the original potency of a lot prior to inactivation
(compare lots 3, 4, 5, and 6, Fig. 1B). For some lots, the
relative loss of activity differed substantially in mouse and
human cultures. For example, heat inactivation of lot 9 did
not affect its activity in mouse cultures but caused a twofold
CFE decrease in human cultures (Figs. 1A and 1B). We then
asked if the effect of heat inactivation would vary, not only
between species, but between individual bone marrow
donors as well. Heat inactivation of a single FBS lot (No. 1)
significantly reduced CFE in cultures of one human donor but
not in those of four others (Fig. 2).
CFE in different murine strains
Using optimized non-heat-inactivated FBS, CFE varied con-
siderably between inbredmouse strains, with the highest CFE
(mean ± SEM) of 11.5 ± 4.0 per 1 × 105 nucleated marrow cells
in Rosa mice and the lowest CFE of 3.5 ± 1.0 in CBA mice (Fig.
3A). In transgenic mice featuring profound phenotypes, CFEwas radically changed compared with that of their respective
wild-type littermates: increased in MT1-MMP-deficient mice
and in mice with an FGFR3 mutation and reduced in Col1-
caPPR mice (as we reported previously in Kuznetsov et al.,
2004) and in IL-5-overproducing mice (Fig. 3B).
Normal human CFE
In cultures of normal bone marrow from 16 children, ages 6
months to 15 years, CFE varied from 11.3 to 101.3 per 1 × 105
nucleated cells (Table 1), averaging 52.2 ± 4.1 (mean ± SEM).
In specimens of normal bone marrow from eight adults, ages
29 to 76 years, CFE ranged from 12.3 to 56.8 per 1 × 105
nucleated cells (Table 1), averaging 32.3 ± 3.0. Linear
regression analysis revealed a statistically significant inverse
correlation between CFE and the age of normal bone marrow
donors (regression value, r = −0.41, P b 0.05, Fig. 4).
However, the age-related CFE decline was relatively modest
and did not represent changes in orders of magnitude. For
male (n = 7) and female (n = 9) pediatric donors, CFE (mean ±
SEM) was, respectively, 60.3 ± 11.5 and 44.7 ± 9.7, P N 0.05.
For male (n = 2) and female (n = 6) adult donors, CFE was
41.3 ± 15.6 and 28.7 ± 4.6, respectively, P N 0.05.
Pathological human CFE
Among pediatric patients, CFE was drastically decreased in a
patient with achondroplasia (severe achondroplasia with
developmental delay and acanthosis nigricans, or SADDAN)
and elevated in a patient with sickle cell anemia and in one of
two patients with Proteus syndrome. CFE was normal (P N 0.05
in comparison with a group of normal pediatric donors) in
patients with Marfan syndrome, Sprengel deformity, or Blount
disease and in a second patient with Proteus syndrome (Table
2, Fig. 5A). In adult patients, CFE was radically reduced in two
patients with congenital generalized lipodystrophy and in a
Figure 3 CFE in mouse cultures. (A) CFE in cultures from
various strains of inbred mice. Mouse bone marrow cells were
plated in triplicate. Numbers of animals analyzed per strain
were CBA, 11; Rosa, 4; FVB/N, 12; C57Bl, 5; NIH-bg-nu/nu-xid,
2. Only differences between Rosa and CBA and between Rosa and
FVB/N were statistically significant. (B) CFE in cultures from
transgenic mice and their wild-type littermates. Mouse bone
marrow cells were plated in quadruplicate. Numbers of animals
analyzed per line were MT1-MMP deficient, 2 wild type, 2
transgenic; IL-5 overproducing, 2 wild type, 2 transgenic; Col1-
caPPR, 2 wild type, 4 transgenic (CFE previously reported in
Kuznetsov et al., 2004); FGFR3 mutation, 3 wild type, 4
transgenic. ⁎Pb0.05; ⁎⁎Pb0.01; ⁎⁎⁎⁎Pb0.0001.
Figure 4 Correlation between CFE and age in normal human
donors.
86 S.A. Kuznetsov et al.patient with pseudoachondroplasia, significantly decreased in
a patient with Paget disease and in two of three patients with
Job syndrome, and increased in a patient with alcaptonuria.
It was normal in both patients with familial partial
lipodystrophy and in a third patient with Job syndrome
(Table 2, Fig. 5B).
Discussion
The identity of CFU-Fs
Marrow stromal precursor cells, also termed CFU-Fs or cells
giving rise to BMSC colonies in vitro, are thought to arise fromcells with vague morphology and multiple names: adventitial
cells, reticular cells, stromal fibroblasts, stromal cells, bone
marrow stromal cells (in situ), preadipocytes, and Westen–
Bainton cells. These cells form a subendothelial (adventitial)
layer of sinusoidal walls and project away extensive processes
that are associated with hematopoietic cells (Bianco and
Riminucci, 1998). They express low levels of collagen types I
and III and osteonectin and are, therefore, considered
fibroblastic (Bianco et al., 1999; Owen and Friedenstein,
1988). These cells also coexpress alkaline phosphatase
(Westen and Bainton, 1979), endoglin (CD105), and high
levels of CD146, the latter being a major hallmark of all CFU-
Fs in vitro and of subendothelial cells in vivo (Sacchetti et al.,
2007). After marrow cell suspension is plated in vitro, those
reticular cells that attach to the culture vessel and begin to
proliferate to form BMSC colonies are, in fact, CFU-Fs
(Friedenstein, 1990; Friedenstein et al., 1990). Thus, the
CFE reflects the prevalence of stromal clonogenic precursors,
or CFU-Fs, in bone marrow. Important to this point, accurate
determination of CFE is highly dependent on the ability of the
culture conditions to support proliferation of CFU-Fs and
their descendants; suboptimal conditions may permit only a
proportion of existing CFU-Fs to form colonies. Consequently,
we analyzed the influence of culture conditions on BMSC
colony formation and then used optimized conditions to study
the variability of CFU-F concentration in various mouse and
human marrow cell populations.
The use of terms and abbreviations: CFU-F, BMSC,
SSC, MSC
At this point, it seems appropriate to discuss the terminology
used for fibroblast-like cells in adherent bone marrow cell
cultures and demonstrate that the terms used in this paper
are neither redundant nor interchangeable. Indeed, “colony-
forming unit–fibroblastic,” or CFU-F, is an in vitro term
encompassing those members of an in vivo Westen–Bainton
cell population that, under actual culture conditions, form
adherent colonies. The original CFU-Fs, as such, cease to
exist after the first cell division in vitro. The colonies formed
by CFU-Fs, as well as the ensuing passaged cell lines, consist
of bone marrow stromal cells (in vitro), or BMSCs; this term,
thus, represents culture-derived progenitors of CFU-Fs. By
Table 2 Pathological donors
Patient Age
(years)
Gender Location Diagnosis Reference CFE/1×105 nucleated
cells (mean±SEM)
Pediatric (age below 18 years)
1 15 F Vertebra Achondroplasia (SADDAN) OMIM 134934 (Bellus et al., 1999) 1.1±0.5
2 14 F Sternum Marfan syndrome OMIM 154700 (Robinson and Booms,
2001)
25.5±1.9
3 5 M Scapula Sprengel deformity OMIM 184400 (Khairouni et al., 2002) 44.8±4.2
4 17 M Face Proteus syndrome OMIM 176920 (Biesecker, 2001) 41.7±2.0
5 9 M Forehead Proteus syndrome 180.0±15.3
6 13 M Iliac
crest
Blount disease OMIM 188700 (Thompson and Carter,
1990)
77.3±1.3
7 4 F Femur Sickle cell anemia OMIM 603903 (Lonergan et al., 2001) 630.3±17.3
Adult (age above 18 years)
1 31 M Iliac
crest
Congenital generalized lipodystrophy
OMIM 269700
(Garg et al., 1999;
Magre et al., 2001)
0.03±0.02
2 29 F Iliac
crest
Congenital generalized lipodystrophy 0.47±0.27
3 48 F Iliac
crest
Familial partial lipodystrophy
OMIM 151660
(Hegele, 2000) 18.5±0.9
4 27 F Iliac
crest
Familial partial lipodystrophy 25.0±2.7
5 36 F Iliac
crest
Pseudoachondroplasia OMIM
177170
(Deere et al., 1998) 1.5±0.6
6 30 F Iliac
crest
Job syndrome OMIM 243700 (Grimbacher et al., 1999) 2.0±0.03
7 42 M Iliac
crest
Job syndrome 11.7±3.5
8 31 F Iliac
crest
Job syndrome 29.7±0.9
9 75 F Tibia Paget disease of bone OMIM 602080 (Reddy et al., 2001; Robey
and Bianco, 1999)
6.2±1.1
10 58 F Knee Alcaptonuria OMIM 203500 (Albers et al., 1992) 120.5±6.1
CFE, colony-forming efficiency.
87Enumeration of CFU–fibrolast from bone marrowclonal analysis, it was demonstrated that only some CFU-Fs
have stem cell properties, capable of both extensive
proliferation and in vivo differentiation intomultiple skeletal
cell types: osteoblasts, chondrocytes, adipocytes, fibro-
blasts, and adventitial reticular cells. Such CFU-Fs are thus
termed “skeletal stem cells,” or SSCs (Bianco et al., 2008);
the continuous existence of SSCs among BMSC populations
renders the latter multipotential. It is not knownwhat part of
BMSCs are SSCs: certainly, less than 20–30% that are normally
clonogenic, or able to form secondary colonies, since
clonogenicity is necessary but not sufficient to grant stem
cell status. This question may be directly answered by clonal
analysis of secondary BMSC colonies.
Contrary to the three above-mentioned terms, the widely
used term “mesenchymal stem cells,” or MSCs, seems
inappropriate for several reasons. First, MSC populations
are heterogeneous, with only some of these cells possessing
stem cell properties; it is, therefore, misleading to call all of
them “stem cells.” Second, the nonskeletal mesenchymal
potential of MSCs (ability to create tissues such as skeletal
muscle, myocardium, and smooth muscle) has not been
formally proven in vivo (Bianco et al., 2008). Thus, the
majority of the “mesenchymal stem cells” are, in fact,
neither stem nor mesenchymal. Finally, the term “MSCs” isinconvenient because, contrary to “BMSCs,” it carries no
information regarding the tissue origin of the cells.
Variability of FBS lots
It has long been practical knowledge that growth-promoting
activity varies between FBS lots, but analysis of the molecules
underlying the differences in such a complex mixture as FBS is
not yet feasible. This causes laboratories to perform routine
FBS trials and to use “preselected” lots thereafter (Lennon et
al., 1996; Mannello and Tonti, 2007). Here, we document that
FBS lots do, indeed, vary broadly in their support of BMSC
colony formation and that the relative quality of the lots is a
species-related phenomenon. Certain lots inferior in mouse
cultureswere among thebest in human cultures andvice versa.
Our data indicate that FBS testing needs to be performed sepa-
rately for BMSCs from each species under study.
FBS heat inactivation: why is it harmful for BMSC
colony formation?
To our knowledge, this report is the first formal comparison
between heat-inactivated and non-heat-inactivated forms of
Figure 5 CFE in cultures from normal and pathological human
donors. (A) Pediatric patients b18 years of age. (B) Adult
patients N18 years of age. Each black bar represents a single
donor, an average of three or four cultures. All differences are in
comparison with the CFE values of age-matched groups of
normal donors (striped bars). ⁎Pb0.05; ⁎⁎Pb0.01.
88 S.A. Kuznetsov et al.FBS as related to BMSC colony formation. Heating serum, as a
means of complement inactivation and prevention of
complement-mediated cell lysis, has been regarded as a
mandatory step for a wide range of cell cultures (Giard,
1987; Leshem et al., 1999). Yet FBS heat inactivation was
found to be unnecessary for immune responses in vitro, such
as lymphocyte proliferation, IL-2 production, and cell-
mediated cytotoxicity (Leshem et al., 1999), as well as for
cell attachment to plastic (Giard, 1987). Beyond such limited
data, the effect of FBS heat inactivation on cell behavior has
long been neglected (Mannello and Tonti, 2007). Our
previous studies have always utilized non-heat-inactivated
FBS based on early work by Friedenstein and coworkers
(Friedenstein, 1990; Friedenstein et al., 1990). In this study,
using both mouse and human BMSC colony formation assays,
not a single FBS lot improved its performance following heat
inactivation. On the contrary, many heated lots demon-
strated significantly reduced ability to promote BMSC colony
formation. The degree of CFE reduction was not dependent
on the original potency of a lot and was both species- and
donor-related. Our findings imply that for both mouse and
human BMSC colony formation, heat inactivation of FBS is
contraindicated. Keeping in mind that the formation of BMSC
colonies by CFU-Fs represents the first, crucial step of BMSC
in vitro generation, the same conclusion will most likely
apply to the entire process of mouse and human BMSC ex vivoexpansion. Our results may be explained by the fact that
heat inactivation reduces the concentrations of several
serum growth factors, including PDGF-BB and HGF (Ayache
et al., 2006), although neither any known growth factor
alone nor any combination of growth factors can substitute
for FBS (Kuznetsov et al., 1997a). In addition, the presence of
intact complement in noninactivated FBS may cause little or
no harm because, on one hand, FBS contains just a fraction of
adult levels of all complement components and, on the other
hand, heating has a dual effect of decreasing titers of C1, C2,
C7, and C8 but increasing titers of C3 and C6 by inactivation
of a heat-labile inhibitor (Linscott and Triglia, 1981).
Our data indicate that BMSC populations generated in
medium with heat-inactivated and noninactivated FBS may
differ with respect to their proliferation histories. It would
be interesting to analyze whether these two populations vary
in other fundamental aspects, such as differentiation
potential, proliferation ability, or cell surface characte-
ristics. Such comparison, however, would represent a much
broader approach than that employed in this study, which
was, by design, limited to the analysis of BMSC colony
formation and CFU-F concentration under a variety of
conditions.Mouse CFE: variability and its possible causes
Using optimized culture conditions, we found CFE to range
from 3.5 to 11.5 per 1 × 105 nucleated marrow cells in inbred
mouse strains. It needs to be acknowledged that the precise
physiological basis of such CFE variability is currently not
clear; in other words, the observed variations in CFU-F
numbers cannot be correlated with any apparent biological
difference related to bone or marrow biology in different
mouse strains. It has been shown, however, that CFU-F
numbers in rats correlate with changes in bone anabolic
activity observed after ovariectomy and the administration
of bone anabolic drugs (Nishida et al., 1994; Scutt et al.,
1996). It is also well recognized that mouse strains show
considerable variation in the quantity and biomechanical
quality of their bones independent of aging (see Jepsen
et al., 2003, for example). While biomechanical bone quality
is often related to architectural features that vary between
mouse strains, it is also possible that the quantity and quality
of bone can result from changes in the number and activity of
stromal cells/SSCs. Earlier, CFE was shown to vary 10-fold
depending on the mouse strain, from 0.03 to 0.3 per 1 × 105
nucleated marrow cells (Phinney et al., 1999). While the
finding of strain-related variability is consistent with our
data, the extremely low CFE values observed in the aforesaid
study imply the apparent loss of 90 to over 99% of CFU-Fs.
This loss can be explained by substandard culture conditions
employed, such as very high plating density (2.5 × 107 cells
per 9.5 cm2, or 65 times higher than in the current paper)
and lack of irradiated marrow cells.
In addition to inbred mouse strains, our study also
included four lines of transgenic mice. In all of them, CFE
was considerably altered, either increased or decreased, in
comparison with their respective wild-type littermates; such
dramatic CFE changes corresponded well to profound bone
phenotypes. Interestingly, in mice bearing an activating
FGFR3 mutation (G369C) (Chen et al., 1999), CFE was altered
89Enumeration of CFU–fibrolast from bone marrowin a direction opposite that of a patient with SADDAN caused
by another activating FGFR3 mutation (K650M) (Iwata et al.,
2001).
Normal human CFE and the need for adequate
culture conditions
In normal human marrow, the average CFE was 52.2 for
children and 32.3 for adults. Our values for normal human
CFE are in agreement with some earlier publications
(Akintoye et al., 2006; Doucet et al., 2005; Kuznetsov and
Gehron Robey, 1996; Kuznetsov et al., 2000; McIntyre and
Bjornson, 1986; Nagao et al., 1983b; Vladimirskaia et al.,
1989), but are considerably higher than CFE values reported
elsewhere: below 1 (Beresford et al., 1994), around 1
(Vladimirskaia, 1977), or below 3 per 1 × 105 nucleated
marrow cells (Bernardo et al., 2007; Oreffo et al., 1998a,
1998b). Such diminutive CFE values suggest, once again, that
over 90% of the existing CFU-Fs were unable to form colonies
because of inadequate conditions of either cell preparation
(density gradient centrifugation during which CFU-Fs may be
lost) or cell culture (most probably a substandard serum). It
must be emphasized that it is not known whether any
particular subset of CFU-Fs is preferentially lost in cultures
with low CFE. However, SSCs, which are deeply quiescent in
vivo, may be critically dependent upon strong growth factor
stimulation to initiate colony formation; they may therefore
be the first subset to be lost under substandard conditions. In
this study, an inverse correlation between normal human CFE
and donor age was observed. This is in agreement with the
majority of earlier publications (D’Ippolito et al., 1999;
Galotto et al., 1999; Kolesnikova et al., 1978; Mets and
Verdonk, 1981; Nishida et al., 1999; Rogova et al., 1981), but
contradicts several others (Oreffo et al., 1998a, 1998b;
Stenderup et al., 2001). The slight decrease that we noted
with aging may be related to a slower rate of fracture healing
in the elderly.
Question of reproducibility of human
CFU-F enumeration
In this study, only a single marrow specimen could be
obtained from the majority of donors, not allowing us to
measure directly the reproducibility of human CFU-F
enumeration. In two cases, however, in which repeated
biopsies from the same donor were available, 10 and 12
months apart, close CFE values were received (not shown). A
possible source of CFE variability could also be due to
different CFU-F concentrations in various parts of the
skeleton. In this study, most adult specimens, both normal
and pathological, were obtained from the iliac crest, thus
eliminating the concern of location-caused variability. Speci-
mens from most normal pediatric donors were also from the
iliac crest; however, marrow from each pathological pedia-
tric donor was obtained from a different site of the skeleton
(Table 2). According to earlier publications, CFE values in
human donors may, indeed, vary depending on the part of the
skeleton; values for iliac crest differ from those for sternum,
femur, tibia, maxilla, andmandible by the factor of 1.5 to 3.5
(Akintoye et al., 2006; Astakhova and Panchenko, 1991;
Suzuki et al., 2001). Meanwhile, in this study, CFE values forpathological pediatric donors differed from normal values by
a factor of 47 [achondroplasia (SADDAN)] or 12 (sickle cell
anemia), considerably surpassing a possible variability
caused by location.Human CFE in various pathological conditions:
a review of the literature
Postnatal stromal cells/SSCs are central mediators of
skeletal homeostasis owing to their participation, not only
in new bone formation, but also in the control of bone
resorption (Bianco and Robey, 2004). It has been our
hypothesis that any genetic defect (intrinsic factor) or
change in the microenvironment (extrinsic factor) that alters
the numbers or the biological activity of stromal cells/SSCs
will lead to skeletal abnormalities (Bianco and Robey, 1999).
In a review of the literature, we noted that CFE was
decreased in patients suffering from alcoholism, a condition
associated with reduced bone mass and osteoporosis
(Giuliani et al., 1999). In patients with osteoporosis per se,
however, CFE was normal (Oreffo et al., 1998a; Stenderup
et al., 2001), as it was in patients with osteoarthritis of the
hip or knee (Majors et al., 1997; Oreffo et al., 1998a, 1998b).
Decreased CFE characterized patients with delayed fracture
healing (Zaritskii et al., 1983), nonunions (Seebach et al.,
2007), and complicated or unsuccessful recovery after
surgery for osteomyelitis (Astakhova, 1988). It has been
reported that CFE is higher in males than in females, and that
in females, it is increased after multiple fractures (Seebach
et al., 2007).
Owing to the central role that stromal cells/SSCs play in
the support of hematopoiesis (Bianco and Robey, 2004),
changes in CFE may be reflective of not only diseases of bone
tissue proper, but also hematopoietic disorders, even in the
absence of overt histological changes in bone, or stroma,
which is not easily imaged. CFE was shown to be normal in
some hematological disorders (Bianchi Scarra et al., 1983;
Domracheva et al., 1980, 1981a, 1981b; Hirata et al., 1989;
Kaneko et al., 1982) and decreased in others (Carlo-Stella
et al., 1997; Domracheva et al., 1981a, 1981b, 1982, 1984;
Duhrsen and Hossfeld, 1996; Hirata et al., 1986; Hotta, 1983;
Kaneko et al., 1982; Katsuno et al., 1986; Nagao et al., 1981,
1983a; Nara et al., 1984), while under certain conditions, it
varied depending on the stage of a disease (Hirata et al.,
1986; Kaneko et al., 1982; Katsuno et al., 1986). CFE values
were found to have prognostic significance in patients with
acute leukemia (Hirata et al., 1986; Katsuno et al., 1986) and
Hodgkin disease (Baisogolov et al., 1973, 1976; Rudakova,
1978). More recently, decreased CFE was observed in
patients with untreated lung carcinoma (Chasseing et al.,
1997a) and breast cancer (Chasseing et al., 1997b), as well as
following chemo/radiotherapy in bone marrow transplant
recipients (Galotto et al., 1999), particularly in those
suffering from acute graft versus host disease (Okamoto
et al., 1991). Notably, low CFE correlated with reduced bone
mineral density in transplant recipients (Galotto et al.,
1999). The findings related to diseases of both bone and
hematopoietic marrow demonstrate the potential impor-
tance of CFE for both prognosis and therapeutic choices in
these conditions and highlight the need for accurate
determinations of CFE.
90 S.A. Kuznetsov et al.Human CFE in several pathological conditions:
novel findings
Our study describes, for the first time, CFE values for several
skeletal, metabolic, and hematological pathologies. CFE was
dramatically decreased in patients with congenital general-
ized lipodystrophy, pseudoachondroplasia, achondroplasia
(SADDAN), and Paget disease of bone and radically increased
in patients with alcaptonuria and sickle cell anemia. CFE
values were mixed (normal in some but abnormal in others)
in patients with Job syndrome and Proteus syndrome; it is
now recognized, however, that patients diagnosed with
Proteus may have various subtypes of the syndrome. CFE
was normal in patients with Marfan syndrome, Sprengel
deformity, Blount disease, and familial partial lipodystrophy.
A decrease in CFE in congenital generalized lipodystrophy
may reflect changes in the hematocrit that have been
observed in these patients (personal communication,
Dr. Philip Gorden, NIDDK, NIH), whereas the increased CFE
noted in the sickle cell anemia patient may very well reflect
the need for an increased support of hematopoiesis by
stromal cells/SSCs, based on the destruction of abnormal
blood cells. In late-stage Paget disease, a decrease in CFU-F
numbers could be the result of multiple rounds of bone
turnover leading to SSC depletion. The potential role of
stromal cells/SSCs in the other disorders studied here is not
immediately apparent, but warrants further investigation.
Despite the lack of in-depth analyses of the human diseases
studied, our current data have a broader implication
demonstrating that in a substantial number of skeletal,
metabolic, and hematological disorders, CFE, indicative of
stromal cell/SSC content, is considerably and variably
affected, reflecting the disturbed status of the bone marrow
stromal compartment. It would be of interest to determine if
abnormal CFE values described for these bone- and marrow-
related pathologies could serve as diagnostic and prognostic
factors, as well.Conclusions
In conclusion, marrow CFU-F numbers were analyzed in a
series of normal and transgenic mice, as well as in normal
human donors and in patients with several skeletal, meta-
bolic, and hematological pathologies. Our findings indicate
that CFE values, which critically rely on the use of
appropriate culture conditions, are substantially abnormal
in many pathologies and may provide useful insights into
pathogenetic mechanisms of bone/bone marrow disorders.
Materials and Methods
Bone and marrow specimens
Bone marrow from 2- to 6-month-old CBA, FVB/N, Rosa 26
[BALB/cJ-TgR(ROSA26)26Sor], C57Bl/6, and NIH-bg-nu/
nu-xid female mice and 5- to 10-week-old Hartley male
guinea pigs (Charles River Laboratories, Raleigh, NC, USA)
was used in mouse experiments. Additionally, marrow from
2- to 4-month-old transgenic mice featuring profound
abnormalities in bone structure and metabolism, and fromtheir wild-type littermates, was studied. The four transgenic
lines were MT1-MMP-deficient, mice lacking membrane-
bound matrix metalloproteinase (Holmbeck et al., 1999);
IL-5-overproducing, mice constitutively overexpressing IL-5
from T cells (Macias et al., 2001); Col1-CaPPR, mice
expressing constitutively active parathyroid hormone/para-
thyroid hormone-related peptide receptor under the control
of the 2.3-kb bone-specific mouse Col1A1 promoter/enhan-
cer (Calvi et al., 2001); and mice harboring activating FGFR3
mutation (G369C) (Chen et al., 1999). Animals were
sacrificed by CO2 inhalation in compliance with an institu-
tionally approved protocol for the use of animals in research
(Protocol 00-113). Femora, tibiae, and humeri were asepti-
cally removed and cleaned of adherent soft tissues.
Specimens of human bone were received in accordance
with NIH regulations governing the use of human subjects
under Protocols 94-D-0188, 97-D-0055, 98-D-0145, and
01-D-0184. Normal bone was obtained from either healthy
volunteers who received a bone biopsy or as surgical waste
from individuals undergoing surgery for trauma or corrective
surgery (Table 1). Patients who had proven or presumable
bone/bone marrow pathology were considered “pathologi-
cal” (Table 2). For each patient, the diagnosis was provided
by a physician responsible for the case. From the majority of
donors (normal or patients), surgical specimens of bone with
marrow were obtained. In the remaining cases, 1.4-mm bone
core biopsies, together with aspirates, were obtained using a
Jamshidi needle; for CFE experiments, only marrow from the
core was used, while the aspirates were excluded to avoid
variable degrees of peripheral blood contamination.
Cell suspensions
Bone marrow single-cell suspensions were prepared as
described previously (Kuznetsov and Gehron Robey, 1996;
Kuznetsov et al., 1997a, 1997b). Briefly, mouse and guinea
pig bone marrow was flushed from the medullary cavities
with α-modified minimum essential medium (αMEM; Invitro-
gen, Grand Island, NY, USA). Fragments of human trabecular
bone and marrow were scraped with a steel blade into αMEM.
The marrow preparations were then pipetted repeatedly to
suspend the marrow cells and consecutively passed through
16- and 20-gauge needles to break up cell aggregates. The
resulting cell suspensions were filtered through a 2350 nylon
cell strainer (Becton–Dickinson, Franklin Lakes, NJ, USA) to
remove the remaining cell aggregates.
Colony formation assay in primary marrow
cell cultures
For the BMSC colony formation assay, marrow single-cell
suspensions were plated in either triplicate or quadruplicate
into 25-cm2 filter cap tissue culture flasks (Nalge Nunc
International, Naperville, IL, USA) containing 5 ml of medium
at the following densities: for mouse, 10 × 105, and for
normal human specimens, 1–2 × 105 nucleated cells per
flask. These cell numbers were selected based on the results
of previous experiments such that discrete BMSC colonies
would be formed in numbers sufficient for statistical
analysis. In pathological human cases in which abnormal
CFE could be expected, additional culture groups were
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marrow cell numbers per flask.
Growth medium consisted of αMEM, 2 mM glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin sulfate (Invi-
trogen), and 20% FBS. The experiments comparing CFE in
normal and pathological specimens of mouse and human
marrow were carried out from 1994 to 2004 and employed
the best FBS non-heat-inactivated lots available at the time
(Invitrogen; Atlanta Biologicals, Inc., Norcross, GA, USA;
Equitech-Bio, Kerville, TX, USA). A new lot was always
chosen based on its ability to support both mouse and human
CFE values comparable to the previous selected lot (see
Figs. 1A and 1B, solid bars, as an example of how testing was
conducted).
In experiments comparing the effects of noninactivated
and heat-inactivated (56°C, 40 min) sera, FBS from 11 lots
manufactured by five companies (Atlanta Biologicals; Bio-
fluids, Inc., Rockville, MD, USA; Equitech-Bio; Gemini
Bioproducts, Inc., Woodland, CA, USA; HyClone Laboratories,
Inc., Logan, UT, USA) was used.
Mouse and human CFE cultures
In addition to FBS, mouse CFU-Fs (plated at low density)
require extra stimuli provided by irradiated marrow cells to
achieve optimal colony formation, while human CFU-Fs form
the maximum number of colonies in just FBS-containing
medium (Friedenstein et al., 1992; Kuznetsov and Gehron
Robey, 1996; Latsinik et al., 1990). Consequently, mouse and
human assays were performed differently. In mouse cultures,
the whole marrow cell population was incubated for 2–4 h,
the time sufficient for CFU-Fs to adhere to plastic (Castro-
Malaspina et al., 1980; Latsinik and Epikhina, 1973). Then,
nonadherent cells were aspirated, the cultures were washed
with αMEM, and fresh growth medium was added. At this
step, freshly prepared guinea pig bone marrow cells,
γ-irradiated with 6000 R to prevent their proliferation
(Friedenstein et al., 1992; Kuznetsov and Gehron Robey,
1996), were added at 1.0 × 107 nucleated cells per flask. In
each mouse experiment, two or three extra flasks containing
just irradiated guinea pig cells were prepared to ensure that
these cells form no colonies on their own. No further medium
replacements were performed thereafter. In human cul-
tures, the entire population of plated cells was left undis-
turbed until harvest.
Cultivation and harvest
Cultivation was performed at 37°C in a humidified mixture of
5% CO2 with air. On day 9 to 12, the cultures were washed
with Hanks’ balanced salt solution (Invitrogen), fixed with
absolute methanol, and stained with a saturated aqueous
solution of methyl violet (Sigma, St. Louis, MO, USA). BMSC
colonies containing 50 or more cells were counted using a
dissecting microscope, and CFE (number of colonies per
1 × 105 nucleated marrow cells) was calculated.
Statistical analysis
Regression analysis was done using Microsoft Excel (Micro-
soft, Redmond, WA, USA). Unpaired t test, Welch corrected,or analysis of variance and posttest comparison using the
Bonferroni multiple comparison test (InStat, GraphPad, San
Diego, CA, USA) was performed. Differences were consi-
dered statistically significant at P b 0.05. In all figures, each
bar represents the mean + SEM; ⁎P b 0.05; ⁎⁎P b 0.01;
⁎⁎⁎P b 0.001; ⁎⁎⁎⁎P b 0.0001.
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